Controlled Drugs Licensing and Proceeds

David Hardstaff and John Binns write for Open Access Government exploring shifting sands in the UK CBD industry

13th May 2022
Cannabis investing group, Controlled Drugs Licensing and Proceeds, David Hardstaff, John Binns, News, News & Insights
UK-based CBD companies may feel they have had a rough ride recently as the FSA introduces the new novel food application process, which requires non-medicinal CBD products to be the subject of an application for authorisation. BCL partner John Binns and senior associate David Hardstaff explore the changes in the UK CBD industry in their recent article for Open Government Access.

Read more

TIGRR: Is it a wonderful thing for the UK’s Cannabis Industry? – John Binns and David Hardstaff write for Open Access Government

8th November 2021
Cannabis investing group, Controlled Drugs Licensing and Proceeds, David Hardstaff, John Binns, News, News & Insights
BCL partner John Binns and associate David Hardstaff ask if a new report should put a spring in the step of UK businesses with an interest in medicinal cannabis and cannabidiol (CBD) in their article published by Open Access Government.

Read more

Can the UK Solve its ‘Money Laundering” Problem with the Proceeds of Medicinal Cannabis? – John Binns and David Hardstaff write for IPI Magazine

15th April 2021
Cannabis investing group, Controlled Drugs Licensing and Proceeds, David Hardstaff, John Binns, News, News & Insights, Proceeds of Crime
BCL partner John Binns and Associate David Hardstaff’s article ‘Can the UK Solve its ‘Money Laundering” Problem with the Proceeds of Medicinal Cannabis?’ has been published by International Pharmaceutical Industry Magazine.

Read more
1 2